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already receiving antimicrobials. We feel that it would have been 
better to screen urine samples received for culture for the presence 
of any antimicrobials in the sample to ensure judicious therapeutic 
intervention.
Recently, investigators at the Hamad Medical Corporation, 
Doha, Qatar, carried out antibiotic screening of 1 680 urine samples 
(employing Escherichia coli ATCC 25922 and Staphylococcus aureus 
ATCC 25923) that were being processed for culture. There were 
2 494 culture-positive urine samples that included 388 samples with 
antibacterial substances. Among these samples were 345 sterile samples, 
32 with insignificant growth samples, and 11 with mixed growth.2
Screening urine samples received at 3 Military Hospital in 
Bloemfontein1 would not be an insurmountable task. Antibacterial 
substance screening of urine samples was feasible even more than 40 
years ago at the All India Institute of Medical Sciences, New Delhi, 
India,3 where screening of 426 urine samples was done by employing 
the standard Oxford strain of S. aureus. There was demonstrable 
antibacterial activity in 127 samples, accompanied by bacterial 
growth in 63 samples. Isolates included E. coli – 28 isolates, Klebsiella 
species – 13, Pseudomonas aeruginosa – 10, Proteus spp. – 6, S. aureus 
– 3, Alkaligenes faecalis – 2, and Streptococcus faecalis – 1. A history of 
prior antibiotic use could be obtained in 25 cases only, though there 
was no relevant information in the laboratory requisition slips. It was 
also possible in 7 cases to identify the antibiotics being used by the 
patients. The isolates in the urine samples were resistant in vitro to the 
prescribed antibiotics. Even with an adequate amount of antibiotic in 
the urine, there was little benefit to the individual.
Obviously, any sterile culture report on a urine sample from a 
patient with a demonstrable antibacterial activity could be erroneous 
unless a subsequent urine culture is found to be sterile. Laboratory 
personnel would not ignore patients with rather low bacterial counts 
in any urine sample with concurrent antibacterial activity. Such 
isolates might represent either a declining population of susceptible 
bacteria or an ascending antibiotic-resistant bacteria population.
Last but not least, any expenditure for carrying out concurrent 
screening for antibacterial substances in all urine samples cultured 
at 3 Military Hospital in Bloemfontein1 or elsewhere would be 
cost-effective, and will lead to better management of urinary tract 
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Dr van Vuuren replies: All urine samples included in our study 
were processed by the National Health Laboratories Services (NHLS) 
in Bloemfontein. In line with standard procedure, Bacillus subtilis 
ATCC 6633 was used to screen for the presence of antibiotics, and a 
leukocyte count performed on all urine samples sent for culture at the 
NHLS. If there is no growth of bacteria in the presence of antibiotics, 
significant numbers of leukocytes warrant further investigation.
As we excluded culture-negative samples from our analysis, we 
obviously cannot comment on the number of samples with no 
growth due to the presence of antibiotics. Apart from the possibilities 
mentioned in our article, antibiotic administration prior to sample 
collection may be another cause for negative cultures.
Questioning the UCT Lung Institute
To the Editor: The enthusiastic account of the 10th anniversary of UCT’s 
Lung Institute (Pty) Ltd in the June issue1 raises many questions. Is medicine 
a caring profession or a business? Is it desirable that the replication of such 
initiatives be encouraged? Is it possible to replicate it even if one wanted to? 
Is the Institute sustainable in the light of its dependence on the exceptional 
ability and determination of a unique individual?
Judged as a business, the Lung Institute seems to be a resounding 
success. Starting 10 years ago with a little ‘nest egg’ and support 
from a pharmaceutical company, it is now a limited company with a 
budget, according to Professor Eric Bateman – founder and CEO – of 
R40 million a year.
Although it sounds as if he is proselytising, Professor Bateman says 
he is not, and I believe him. To enable others to follow would require 
that he instruct them in the finer arts of the business such as how 
the Institute is kept ‘light on its feet’ and circumvents burdensome 
bureaucracy, which he identifies as ‘the enemy of enterprise’. Every 
successful businessman is entitled to his secrets, and no businessman 
in his right senses would deliberately open up his market to 
competition.
However much I admire the achievement, I find the self-promotion 
distasteful. There are several aspects of the arrangement that I don’t 
understand, and one of them is of deep concern.
What I don’t understand is what the university gets out of its 
wholly owned tax-free subsidiary for ‘educational and charitable 
purposes’. There are presumably no dividends, because ‘Surpluses are 
utilised for the activities of the institute in pursuant of goals’.2
How much does UCT earn from government subsidies from 
Institute publications in peer-reviewed journals? How does the 
Institute add value to the core university function of teaching? 
A few postgraduate researchers are mentioned, but what about 
a contribution to medical student and postgraduate registrar 
instruction and supervision?
What is of greatest concern to me is the fact that the Lung Institute 
and GINA3 –  the Global Initiative for Asthma, of which Professor 
Bateman has been appointed [sic] Chair of the Executive and 
Science Committees4  – are both dependent for their existence on the 
pharmaceutical industry.5
For me it’s like a nightmare come true. At about the time the Lung 
Institute was founded, John Le Carré, the noted author, was warning:
‘But Big Pharma is also engaged in the deliberate seduction of the 
medical profession, country by country, worldwide. It is spending a 
fortune on influencing, hiring and purchasing academic judgement 
[sic] to a point where, in a few years’ time, if Big Pharma continues 
unchecked on its present happy path, unbought medical opinion will 
be hard to find.’6
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SAMJ News Editor Chris Bateman replies: The article was the 
result of a confluence of events. Firstly, several deans of medicine 
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had painted an alarming picture to the Parliamentary Portfolio 
Committee on Health of dysfunctional funding of tertiary institutions 
and, more importantly, the paucity of medical clinical research in this 
country; this remained fresh in my mind. Secondly, having reported 
on some exemplary application of the Lung Institute’s research in 
the field, I decided that its 10th anniversary was worthy of coverage, 
given the context of which I’d recently become aware. The Institute’s 
achievements speak for themselves. While the long-distance runner 
metaphor may have sounded ‘enthusiastic’, the facts made it a readily 
available journalistic tool to convey the message in an entertaining 
way. As for being ‘distasteful’, that’s a matter of opinion and goes 
to a debate that Professor Klein has raised – which my article did 
not speak to. Lastly, and perhaps pertinently for the record (given 
the literary enthusiasm I displayed), a disclaimer was printed at the 
bottom of the article stating that I am in no way related to Professor 
Bateman. Professor Klein puts an entirely different set of issues on 
the table, and if my article ‘raises many questions’, that is in keeping 
with my job.
Professor S R Benatar, Acting Chair, on behalf of the University 
of Cape Town Lung Institute directors, replies: In response to Max 
Klein`s uninformed criticisms and questions about the Lung Institute 
based on a news report, we begin by recommending that he read the 
10-year formal report of the Lung Institute’s activities (http://www.
lunginstitute.co.za).
As part of the extended Faculty of Health Sciences platform for 
teaching, learning and research, its mission is to serve the University 
of Cape Town, the Faculty of Health Sciences and the community. Its 
widely acknowledged significant contributions to all the above have 
earned its researchers many honours over the past decade. 
Apart from its legal status, the Institute is no different from a large 
research grouping within an academic department. Its academic staff, 
whose work in the Institute is supported by their research income, have 
formal faculty appointments and contribute to teaching (all levels) 
within their departments. Several postgraduate students undertake 
projects in the Institute towards master’s and doctoral degrees, funded 
by the Institute and supervised by Institute academic staff. 
Although the Institute does not directly earn state subsidy, 
publications by its members with UCT appointments draw subsidy 
for UCT, as in any university department. In addition to retaining and 
benefiting from the very considerable outputs of highly motivated 
staff, without having to provide the overheads ordinarily required 
for a large research grouping, numerous collaborations with other 
university departments have generated successful joint grant 
applications, and support for postgraduates. 
The Institute strikingly provides a platform for a wide range of 
socially responsive and public service activities. Senior Institute 
staff deliver regular unpaid clinical and consultation services in the 
Division of Pulmonology, the Department of Critical Care at Groote 
Schuur Hospital and Brooklyn and Brewelskloof TB hospitals, and at 
primary care clinics in the Western Cape. 
Notable academic outputs include studies of the burden of lung 
diseases in South Africa, the testing of new drugs, diagnostics and 
vaccines for tuberculosis, and a reference allergy service. In the field 
of knowledge translation, an innovative, integrated practice manual 
for chronic and infectious diseases for use in primary care clinics has 
been developed, and is being adopted and rolled out in South Africa 
as well as in Malawi and Kenya. The Knowledge Translation Unit has 
trained more than 800 nurse trainers and more than 13 000 primary 
care nurses in the use of this integrated care guideline.
While an initial and welcome pharma donation received by UCT 
provided for constructing the building, we refute any misconception 
that the Institute is entirely dependent on the pharmaceutical 
industry. We acknowledge the challenges facing most academic 
institutions worldwide in their relations with industry, but the 
Institute’s 10-year report provides evidence for the success of our 
endeavours to become increasingly independent from such support. 
For several years, income from grants and non-pharmaceutical 
sources has exceeded income received from research contracts with 
the pharmaceutical industry. The governing Board of Directors with 
a finance committee appointed by the directors oversees all aspects 
of Institute activities, ensuring that funds obtained through research 
contracts with pharma are raised and utilised transparently, with full 
accountability and in keeping with university policy.
Origin of recurrent Plasmodium vivax 
malaria – a new theory
To the Editor: The phenomenon of long-term relapse is familiar to 
many persons who have contracted malaria, and to their doctors. 
Attacks of Plasmodium vivax malaria (so-called benign tertian malaria) 
in particular can occur after symptomatic illness has been absent in the 
patient for months or years. Recurrent clinical P. vivax manifestations 
have been thought to originate from a dormant liver form, the 
discovery of which1 has become recognised as a classic landmark in 
the history of parasitology and tropical medicine. I correctly predicted 
the existence of the stage concerned (extrapolating from my rodent-
associated research while a PhD student at Imperial College London) 
and coined the term ‘hypnozoite’ for it.2 For the past three decades, 
medical students worldwide have been taught that hypnozoites give 
rise to malarial relapse. However, new findings indicate that there 
might well be a second cause of recurrent P. vivax malaria. 
Parasites responsible for recurrence of benign tertian malaria 
are frequently genotypically different (determined by molecular 
techniques) from those that gave rise to the initial symptomatic bout 
of disease. In other cases, parasites are genetically similar.3,4 The 
genotypes of sporozoites in inocula that are injected into the skin 
by mosquitoes are known to be diverse. Assuming that hypnozoites 
are directly sporozoite-derived (which they appear to be5), and that 
re-infection of any given patient has not taken place, the former 
(heterologous parasite) situation is therefore perfectly compatible 
with the hypnozoite concept of relapse.
I now suggest that there is a possible non-hypnozoite basis for 
the other (i.e. homologous parasite) phenomenon in at least some 
instances. Rodent malarial stages that might become latent for 
extended periods have recently been detected in splenic dendritic 
cells. These parasites are able to infect erythrocytes, and similar 
forms could be responsible for clinical human malaria that follows 
splenectomy for splenic trauma.6 Plasmodial stages like those in 
rodents will obviously now be searched for in dendritic cells from 
human spleens. I speculate that such forms or other merozoites 
may also be the source of recurrent P. vivax episodes which are 
conventionally always ascribed to homologous hypnozoite activation. 
If a recurrent clinical P. vivax attack can indeed be the result of 
renewed asexual reproduction of merozoites following a period of 
dormancy, as I hypothesise, then this would explain why parasites 
isolated from peripheral blood samples in recurrent malaria have 
sometimes proved to be genetically similar to those that were 
responsible for the primary clinical infection. 
It is easier to appreciate the feasibility of this straightforward 
explanation than to imagine what the mechanistic basis of a 
homologous hypnozoite relapse postulation for renewed parasitaemia 
might be. The latter nevertheless remains a possibility. However, why 
some sporozoites of a particular genotype would multiply in the liver 
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